Novocure NVCR 深 沪
等待开盘 09-17 09:30:00 美东时间
12.68
-0.040
-0.31%
华盛通- 最 高12.9222
- 今 开12.88
- 成交量 188.64万股
- 最 低 12.56
- 昨 收 12.72
- 总市值 14.07亿
- 52周最高 34.13
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 10.87
- 委 比 -81.14%
- 总股本 1.11亿
- 历史最高 232.76
- 量 比 1.26
- 振 幅 2.85%
- 历史最低 5.95
- 每 手 1
- 风险率 5.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Japan's Ministry Of Health, Labour And Welfare Approves Novocure's Optune Lua For Concurrent Use With PD-1/PD-L1 Inhibitors For Adult Patients With Unresectable Advanced/Recurrent Non-small Cell Lung Cancer Who Have Progressed On Or After Platinum-Based Chemotherapy
Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical
09-15 19:03
ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma
All five patients in a trial with recurrent glioblastoma given a combination of ImmunityBio's (NASDAQ:IBRX) natural killer (NK) cell therapy Anktiva and Novocure's (NASDAQ:NVCR) Optune Gio Tumor Treat...
08-26 23:21
最新！10款医疗器械进入创新通道
2025年8月5日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第7号），有10款产品进入创新通道。 1.产品名称：产前胎儿畸形...
08-06 11:56
Top 3 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to b...
07-28 18:52
美股周涨跌榜 | 本周飙升568%！Abivax S.A.新药III期研究成功；CRO股Medpace周涨超43%
本周飙升568%！生物技术公司Abivax S.A.溃疡性结肠炎口服药物III期研究成功；CRO股Medpace周涨超43%，Q2营收和EBITDA均超预期>>
07-26 10:23
Wells Fargo Downgrades NovoCure to Equal-Weight, Lowers Price Target to $14.5
Wells Fargo analyst Larry Biegelsen downgrades NovoCure (NASDAQ:NVCR) from Overweight to Equal-Weight and lowers the price target from $40 to $14.5.
07-25 21:22
NocoCure shares are trading lower. The company reported Q2 financial results.
NocoCure shares are trading lower. The company reported Q2 financial results.
07-24 23:05
Earnings Scheduled For July 24, 2025
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is likely to repo...
07-24 16:32
NovoCure Earnings Preview
NovoCure (NASDAQ:NVCR) is set to give its latest quarterly earnings report on T...
07-24 05:02
Ladenburg Thalmann Initiates Coverage On NovoCure with Buy Rating, Announces Price Target of $30
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on NovoCure (NASDAQ:NVCR) with a Buy rating and announces Price Target of $30.
07-08 20:17
